Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Keros Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $17.9 million for Q4 2025.

• Quarterly Research & Development fell 60.75% year-over-year to $17.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.6 million (down 25.33% YoY) and the FY2025 annual result came in at $129.6 million, down 25.33% from the prior year.
• Research & Development was $17.9 million for Q4 2025 at Keros Therapeutics, down from $19.5 million in the prior quarter.
• Across five years, Research & Development topped out at $49.2 million in Q3 2024 and bottomed at $10.0 million in Q2 2021.
• A 5-year average of $29.0 million and a median of $28.0 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 133.21% — and 2025, when it slumped 60.75%.
• Keros Therapeutics' Research & Development stood at $18.8 million in 2021, then jumped by 32.04% to $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then rose by 21.71% to $45.6 million in 2024, then slumped by 60.75% to $17.9 million in 2025.
• Business Quant data shows KROS's Research & Development at $17.9 million in Q4 2025, $19.5 million in Q3 2025, and $43.5 million in Q2 2025.